March 2025 Life Sciences Update
France: Paris
MARKETS CONTENTS
Market Summary
Public & Private Funding (2024)
Fast Lab Stats
• The greater Paris region is the leading life sciences research and university hub in France. Until now, activity in the French life sciences sector has been confidential and led by the public sector, but it has taken on a new dynamic since the pandemic. Through the France 2030 plan, the government has mobilized 30 billion euros for the development of biotech. • Paris lacks private-sector assets that are adapted to scientific and technological research, such as laboratories, research centers and incubators. According to Urban Land Institute, 60% of life sciences companies consider the lack of real estate to be the main obstacle to development in France. • Over the previous five years, Paris has attracted 1 billion euros in VC funding to the life sciences industry. Companies in biotechnology and pharma research have received a significant share of this financing. • When choosing office space in Paris, pharma businesses strongly favor the city's western suburbs. While the life sciences investment market in Paris is still small, there is strong appetite from investors and occupiers, and the market is expected to develop strongly in the next two years. International investors are increasingly considering real estate opportunities in the greater Paris region, led by AXA/Kadans and Oxford Properties/Novaxia. • The Paris region is home to five life sciences clusters: Genopole at Evry and the Cancer Campus at Villejuif to the south, Paris Biocitech in the east, Medicen Campus in the west, and Paris-Saclay to the southwest. The latter offers a unique ecosystem of universities, research centers and companies.
€ Raised (MM)
Company
Deal Type
Completed
VC Round
32.5K Total Life Sciences Employment 119% Life Sciences Employment Growth Rate
Abolis
Later Stage VC
Sep 2024
2nd Round
€ 35.0
Bioptimus
Seed Round
Feb 2024
1st Round
€ 35.0
Biomemory
Early Stage VC
May 2024
2nd Round
€ 17.0
Cure51
Seed Round
Mar 2024
1st Round
€ 15.0
Orakl Oncology
Seed Round
Dec 2024
2nd Round
€ 11.0
Qubit Pharmaceuticals
Early Stage VC
Jun 2024
3rd Round
€ 8.0
Mapreg
Later Stage VC
Jul 2024
5th Round
€ 7.0
Hepta Medical
Later Stage VC
Sep 2024
3rd Round
€ 5.7
Milvue
Later Stage VC
Jan 2024
3rd Round
€ 5.5
Generare
Seed Round
Oct 2024
1st Round
€ 5.0
Representative Investment Sale Transactions (2023 – 2024)
Address
Type
Volume (€m)
GLA (sqm)
Date
Buyer
Engie Lab Crigen
Office/lab
C22
9,000 Q4 2024 Iroko Zen
Romainville
Office/Lab
c.17
33,000 Q1 2023
Novaxia Vista and Oxford Properties
Representative Life Sciences Companies
Life Sciences Labor: Annual Chemist Job Postings
Villejuif
Office/Lab
NC
25,000 Q4 2022 Kadans Science Partner
Company
Type
12,000
Representative Lease Transactions (2023 – 2024)
Sanofi
International HQ
10,000
Ipsen
International HQ
Company
Address
GLA (sqm) New/Renewal
Type
Quarter
Landlord
Laboratoires Roche French HQ
Solabia
17 Place Des Reflets
1,143 Renovated
Office
Q2 2024
8,000
Abbvie
French HQ
Syneos Health
38 Avenue Ariste Briand
1,143 Renovated
Office
Q2 2024 AG Real Estate
6,000
Amgen
French HQ
Abivax
7-11 Boulevard Haussmann
831 Recent/Sublease Office
Q2 2024 Workday
Bristol-Myers Squibb French HQ
4,000
Merck
French HQ
Daiichi Sankyo
8-10 Rue Henri Sainte-Claire Deville
2,500 New
Office
Q1 2024 Sienna IM
Pfizer
French HQ
2,000
BASF
176 Rue Montmartre
2,356 Refubished
Office
Q1 2024 Oreima
Pierre Fabre
International HQ
Ipsen
70 Rue Balard
8,797 Refubished
Office
Q4 2023
CNP (DTZ AM)
-
Boehringer Ingelheim French HQ
2019 2020 2021
2022
Inserm
1-5 Rue Jeanne D'Arc
1655 Refurbished
Office
Q4 2023
Icade
Amgen
25 Quai du President Paul Doumer
2290 Refurbished
Office
Q3 2023
Hines
Bio Degree-Awarding Institutions, Metro Area
70 rue Balard
10,000 Refurbished
Office
Q4 2023
DTZ Investors
Ipsen
Université Paris-Saclay
• • • • • • • • • •
PSL (Paris Siciences et Lettres)
Sorbonne
AgroParis Tech
Sup Biotech
EBI (Ecole de Biologie Insdustrielle)
HEC
Contributor Nicolas Carre Nicolas.carre@cushwake.com
ESSEC
Polytechnique
Insead
Sources: Cushman & Wakefield Research, CoStar, Pitchbook, EFPIA
Cushman & Wakefield
83
Made with FlippingBook - Online magazine maker